Objective: Clinical trials of a brain-responsive neurostimulator, RNS® System (RNS), excluded patients with a vagus nerve stimulator, VNS® System (VNS). The goal of this study was to evaluate seizure outcomes and safety of concurrent RNS and VNS stimulation in adults with drug-resistant focal-onset seizures.
Methods: A retrospective multicenter chart review was performed on all patients with an active VNS and RNS who were treated for a minimum of 6 months with both systems concurrently. Frequency of disabling seizures at baseline before RNS, at 1 year after RNS placement, and at last follow-up were used to calculate the change in seizure frequency after treatment. Data on adverse events and complications related to each device were collected.
Results: Sixty-four patients from 10 epilepsy centers met inclusion criteria. All but one patient received RNS after VNS. The median follow-up time after RNS implantation was 28 months. Analysis of the entire population of patients with active VNS and RNS systems revealed a median reduction in seizure frequency at 1 year post-RNS placement of 43% with a responder rate of 49%, and at last follow-up a 64% median reduction with a 67% responder rate. No negative interactions were reported from the concurrent use of VNS and RNS. Stimulation-related side-effects were reported more frequently in association with VNS (30%) than with RNS (2%).
Significance: Our findings suggest that concurrent treatment with VNS and RNS is safe and that the addition of RNS to VNS can further reduce seizure frequency.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339206 | PMC |
| http://dx.doi.org/10.1016/j.yebeh.2022.108653 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neuromodulation Strategies in Lennox-Gastaut Syndrome: Practical Clinical Guidance from the Pediatric Epilepsy Research Consortium.
Epilepsy Res
January 2025
Jane and John Justin Institute for Mind Health, Cook Children's Medical Center, Ft Worth, TX, USA.
Lennox-Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy characterized by multiple drug-resistant seizure types, cognitive impairment, and distinctive electroencephalographic patterns. Neuromodulation techniques, including vagus nerve stimulation (VNS), deep brain stimulation (DBS), and responsive neurostimulation (RNS), have emerged as important treatment options for patients with LGS who do not respond adequately to antiseizure medications. This review, developed with input from the Pediatric Epilepsy Research Consortium (PERC) LGS Special Interest Group, provides practical guidance for clinicians on the use of these neuromodulation approaches in patients with LGS.
View Article and Find Full Text PDFOn brain stimulation in epilepsy.
Brain
January 2025
Department of Neurosurgery, University of Utah, Salt Lake City, UT 84132, USA.
Brain stimulation has, for many decades, been considered as a potential solution for the unmet needs of the many people living with drug-resistant epilepsy. Clinically, there are several different approaches in use, including vagus nerve stimulation (VNS), deep brain stimulation of the thalamus, and responsive neurostimulation (RNS). Across populations of patients, all deliver reductions in seizure load and SUDEP risk, yet do so variably, and the improvements seem incremental rather than transformative.
View Article and Find Full Text PDFComparative Efficacy of Neuromodulatory Strategies for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis.
World Neurosurg
October 2024
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China; China International Neuroscience Institute, Beijing, China. Electronic address:
Objective: The study aims to evaluate the efficacy of neuromodulatory strategies for people who have drug-resistant epilepsy (DRE).
Methods: We searched electronic repositories, including PubMed, Web of Science, Embase, and the Cochrane Library, for randomized controlled trials, their ensuing open-label extension studies, and prospective studies focusing on surgical or neuromodulation interventions for people with DRE. We used seizure frequency reduction as the primary outcome.
Exercise in patients with epilepsy and neurostimulation devices - physical activity levels, barriers, and beliefs.
Epilepsy Behav Rep
July 2024
Neurology Department, Penn State Health Milton S Hershey Medical Center, 30 Hope Drive, Hershey, PA 17033, USA.
Exercise improves many comorbidities associated with epilepsy in addition to seizure control. Despite the ILAE consensus statement noting the positive effects of exercise in patients with epilepsy (PWE) and individual assessment of risks pertaining to these activities, many healthcare professionals, including neurologists, are unfamiliar with these guidelines. Neurostimulation is an increasingly prevalent treatment option for refractory epilepsy.
View Article and Find Full Text PDFPresurgical Use of Cenobamate for Adult and Pediatric Patients Referred for Epilepsy Surgery: Expert Panel Recommendations.
Neurol Ther
October 2024
Refractory Epilepsy Unit, Hospital Universitari I Politècnic La Fe, Valencia, Spain.
Article Synopsis
- Cenobamate has proven effective for patients with treatment-resistant epilepsy, including those who still experience seizures post-surgery, leading experts to recommend its use during the surgical evaluation process.
- A panel of six epilepsy specialists suggests that both cenobamate and antiseizure medication (ASM) should be personalized and optimized during presurgical evaluations, with cenobamate potentially helping many patients achieve seizure freedom.
- While cenobamate can be initiated before surgery, especially for patients not ideal for surgery, it should not delay necessary operations, and patients may choose to forgo surgery if they attain lasting seizure control with cenobamate.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!